Repligen Corp revenue
Repligen Corp's revenue was $738m in fiscal 2025, up 16.4% on the year before. Since fiscal 2010 ($21.0m) it has grown at a compound 26.8% a year. Over the last twelve months it was $806m.
Revenue history
| Fiscal year | 2010Mar 2010 | 2011Mar 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21 | 27 | 62 | 68 | 64 | 84 | 105 | 141 | 194 | 270 | 366 | 671 | 802 | 632 | 634 | 738 | 806 |
| Growth on the year before | — | +30.1% | +128.2% | +9.5% | −6.8% | +31.5% | +25.1% | +35.1% | +37.4% | +39.3% | +35.5% | +83.1% | +19.5% | −21.1% | +0.3% | +16.4% | — |
| Gross profit | — | — | — | — | — | — | 57 | 74 | 108 | 151 | 210 | 391 | 456 | 278 | 275 | 386 | 431 |
| Gross margin | — | — | — | — | — | — | 54.9% | 52.5% | 55.4% | 55.9% | 57.2% | 58.3% | 56.9% | 44.0% | 43.3% | 52.3% | 53.5% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Products | $738M | 99.5% | ▲ 16.4% |
| Filtration Products (part of Products) | $403M | 54.6% | ▲ 8.0% |
| Chromatography Products (part of Products) | $153M | 20.8% | ▲ 24.7% |
| Proteins Products (part of Products) | $97.4M | 13.2% | ▲ 30.9% |
| Process Analytics Products (part of Products) | $81.2M | 11.0% | ▲ 37.0% |
| Other Products | $3.3M | 0.4% | ▼ 29.0% |
| Royalty | $296,000 | 0.0% | ▲ 13.4% |
From Repligen Corp's 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Repligen Corp | $806m | 13.8% | 7.3% |
| Neogenomics Inc | $788m | 11.1% | 11.1% |
| 10x Genomics, Inc. | $617m | -4.3% | 2.8% |
| Azenta, Inc. | $614m | 4.9% | -0.9% |
| Veracyte, Inc. | $562m | 17.3% | 19.6% |
| Bio-Techne | $1.22bn | -0.4% | 2.2% |
Compare with peers
- Neogenomics Inc revenue
- 10x Genomics, Inc. revenue
- Azenta, Inc. revenue
- Veracyte, Inc. revenue
- Bio-Techne revenue
Head to head: NEO vs RGENRGEN vs TXGAZTA vs RGENRGEN vs TECH
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies